At Bio Vantage, our mission is to provide high-quality equity reports focused primarily on biotech and pharmaceutical companies worldwide. In our view, fundamental analysis of biopharmaceutical companies requires expertise in evaluating clinical trial data and drug pipelines, as these events often drive the underlying equity value of such companies going forward. Equally important is the ability to forecast future revenues, earnings growth, and cash flows using financial modeling tools in order to derive an intrinsic value for the company being analyzed. Once a fundamental value is derived, investors can make profits from a variety of trading instruments. While our expertise largely concerns biotech and pharmaceutical companies, our investment principles are centered on diversification, asset allocation, risk management, and portfolio strategies. Thus, our investments and analyses also cover other sectors, including technology, financials, consumer products, energy, and commodities. Bio Vantage's analysts have extensive experience in the biomedical field and in drug discovery research. We are lifelong investors. One of the analysts holds the CFA charter designation.
My investing activities began with index funds when I was about thirteen. At the age of eighteen, I began investing in individual companies. Since I was always interested in science and technology, I started my focus in tech and biologically focused companies. Currently, I have over three years of experience with investing in individual stocks (primarily in biotech, med-tech, and pharmaceuticals). I focus primarily on small to mid cap companies that exhibit strong revenue growth and/or innovative clinical developments. I am currently an undergraduate student pursuing a degree in Molecular Biology & Biochemistry, with aspirations of getting an MBA in Finance.